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chemotherapy. If conﬁrmed on other patient populations, our ﬁndings 
should signiﬁcantly advance the clinical management of patients with 
completely resected NSCLC. 
The study was supported by an unrestricted grant from Eli Lilly.
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Background: Non-small-cell lung cancer (NSCLC) patients with 
locally advanced or metastatic disease at the time of diagnosis show 
marginal response to chemotherapy in terms of tumor shrinkage, time 
to progression and median survival. MAP4 and stathmin have been pre-
viously reported as potential markers of resistance to treatment based 
on microtubule-destabilizing agents.
Methods: In this multicenter study, we have used quantitative PCR to 
analyze the expression of MAP4, stathmin, beta-tubulin III, BRCA1 
and ERCC1 using mRNA isolated from peripheral blood samples of 51 
non-small-cell lung cancer patients treated with vinorelbine/carboplatin.
Results: In a preliminary set, 46 patients with stage IIIB and IV 
were analyzed. Lower levels of MAP4/OP18 mRNA expression are 
statistically associated with a response to vinorelbine-based treatment 
(p=0.029). This signiﬁcant relationship is maintained in a second analy-
sis after 3rd cycle of treatment (p=0.032). Higher levels of MAP4/op18 
were associated with a lower TTP (p=0.05).
Conclusions: Our preliminary results suggest that the ratio MAP4/
OP18 may be a good predictor of response for NSCLC patients treated 
with vinorelbine-based chemotherapy.
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Objective: To prospectively evaluate the use of positron emission 
tomography (PET) with the glucose analog 18-ﬂuorodeoxyglucose 
(18FDG) to predict best objective response and survival after the ﬁrst-
line chemotherapy in patients with advanced non-small cell lung cancer 
(NSCLC).
Methods: Patients with advanced NSCLC were prospectively enrolled 
into this study to undergo platinum-based doublet chemotherapy. 
Patients were studied by 18FDG-PET before and after the ﬁrst two 
cycles of chemotherapy. A reduction of tumor 18FDG uptake by more 
than 30% as assessed by standardized uptake value(SUV) was used as 
a criterion for a metabolic response. Compare RECIST response with 
18FDG-PET metabolic response by Measure of Agreement Kappa test.
Survival in patients with or without a metabolic response was com-
pared by the log-rank test. Statistical computations were performed 
with SPSS13.0. 
Results: 46 patients with advanced NSCLC (2 cases with wet stage 
IIIB and 44 cases with stageIV) were included in the study. There was 
a close correlation between metabolic response and best objective 
response to the ﬁrst-line chemotherapy according to RECIST, P<0.001; 
Sensitivity, speciﬁcity, accuracy, prediction of positive value and pre-
diction of negative value for prediction of best objective response were 
95%, 65%, 78%, 69% and 94% respectively. By the end of February 
28, 2007, duration of follow-up had been ranged from 1.8 months to 
29.7 months, median survival time for metabolic responders was 13.70 
months, 95% CI (9.08~13.32), and that for metabolic non-responders 
was 12.00 months, 95% CI (6.58~17.43), P >0.05; there is no differ-
ence in overall survival between metabolic responders and metabolic 
non-responders, P >0.05. 
Conclusions: Reduction of SUV in 18FDG-PET after two-cycle 
chemotherapy for advanced NSCLC is closely correlated with best 
objective response. However, up till now, we have not yet observed 
signiﬁcant difference in median survival time and overall survival time 
between metabolic responders and metabolic non-responders.
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Background: The treatment of non-small-cell lung cancer (NSCLC) 
has reached a plateau of effectiveness, but the selection of patients ac-
cording to key genetic characteristics may help to tailor chemotherapy 
and optimise the treatment increasing response rates and survival. Poly-
morphisms within the Xeroderma Pigmentosum Group D (XPD), Exci-
sion Repair Cross-Complementing 1 (ERCC1) and Cytidine Deami-
nase (CDA) genes have been associated with alterations in enzymatic 
activity and may change sensitivity to the widely used platinum-based 
and gemcitabine chemotherapy regimens. We investigated the correla-
tion between selected single nucleotide polymorphisms (SNPs) of these 
genes and the activity and efﬁcacy of chemotherapy.
Methods: Seventy-eight chemotherapy-naïve, advanced NSCLC 
patients were enrolled in the study; 52 were treated with cisplatin/gem-
citabine and 26, aged > 70 years, with gemcitabine alone. Median age 
was 66 years (range 44-81). Association between XPD Asp312Asn and 
Lys751Gln, ERCC1 C118T and CDA Lys27Gln SNPs and treatment 
response, toxicity, time to progression (TTP) and overall survival (OS) 
was estimated using Kaplan-Meier method, Log-rank test and Cox’s 
proportional model. SNPs were analyzed with the ABI PRISM 7900HT 
Sequence Detection System using TaqMan® probe-based assay in DNA 
obtained from peripheral blood samples.
